Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

223,771-223,800 of 319,975

filter-aware
20
The chart uses a waterfall structure to show how specific initiatives (R&D, Engineering, Supply Chain, Operations) reduce the cost components (Materials, Labor, Overhead) over time.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Action1 hit
21
The slide uses stacked bar charts to detail expense categories and a table for peer benchmarking.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Action1 hit
22
Includes a disclaimer about hypothetical scenarios and a project timeline matrix.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Action1 hit
23
The slide uses a 2x2 grid for operational metrics and a vertical list for capital updates.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Action1 hit
24
Eos Energy | Investor Presentation Deck | 24 slidesEos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Action1 hit
01
Slide 1
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
02
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
03
The slide uses a hub-and-spoke diagram to centralize the company brand around key investment pillars.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
04
The slide uses a Gantt-style visualization to show clinical trial phases for different drug candidates.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
05
This is a section divider or introductory slide for the product solution.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
06
The slide details a specific corporate partnership agreement.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
07
The slide uses a side-by-side comparison structure to detail the status and upcoming milestones for two distinct clinical programs.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
Includes a diagram illustrating cytokine-receptor binding and downstream signaling.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a visual comparison to frame the problem of current therapeutic limitations.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Problem (Identify pain)1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The slide highlights the structural commonality of the γC receptor across multiple cytokines, positioning it as a therapeutic target.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide uses a structural biology approach to explain the mechanism of action for their therapeutic platform.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The slide uses a biological process diagram to illustrate how the inhibitor prevents the dimerization of private receptors with the shared receptor.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a visual comparison framework to illustrate the mechanism of action and therapeutic benefits.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
The slide uses a four-column structure to explain the target, molecular nature, preclinical results, and clinical status.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The slide uses a column-based layout to compare four distinct medical conditions, each with specific patient counts and development milestones.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
Includes before/after patient photos and comparative data against Mogamulizumab.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
22
The slide uses a circular process diagram to show the feedback loop of cytokines and immune cells leading to hair loss.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
Includes visual longitudinal data (photos) and quantitative bar chart data.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide compares two different drugs (baricitinib and deuruxolitinib) using their respective clinical trial data (BRAVE AA1 and THRIVE AA1).Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
25
Includes a blackbox warning text block as a competitive/safety barrier context.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit